Literature DB >> 11958858

Inducible nitric oxide synthase and argininosuccinate synthetase: co-induction in brain tissue of patients with Alzheimer's dementia and following stimulation with beta-amyloid 1-42 in vitro.

Jürgen Haas1, Brigitte Storch-Hagenlocher, Annette Biessmann, Brigitte Wildemann.   

Abstract

In Alzheimer's disease (AD), amyloid plaques within the brain are surrounded by activated glial cells (microglia and astrocytes). The mechanisms of glial activation and its effect on disease progression are not fully understood. Growing evidence suggests that beta-amyloid (Abeta) peptide, a major constituent of the amyloid plaque, is critically involved in the induction of an inflammatory response. The goal of this study was to examine the role of Abeta in the pathogenesis of local inflammation and neuronal cell death. We found increased mRNA levels of inducible nitric oxide synthase (iNOS) and the arginine regenerating enzyme argininosuccinate synthetase (ASS) within cortices of AD patients suggesting high output NO production. In vitro, synthetic Abeta1-42 and to a lesser extent Abeta1-40 induced iNOS and ASS transcription with consecutive NO overproduction in mixed rat neuronal-glial cultures. Furthermore, Abeta-stimulation lead to an increased release of inflammatory cytokines interleukin (IL)-1beta, IL-6 and tumor necrosis factor-alpha. Again, Abeta1-42 had a much more pronounced effect as compared to Abeta1-40. Our data suggest that Abeta1-42 is a key mediator of glial activation and via the induction of inflammatory mediators may be a critical component of the neurodegenerative process in AD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11958858     DOI: 10.1016/s0304-3940(02)00095-2

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  28 in total

1.  Higher cardiovascular fitness level is associated with lower cerebrovascular reactivity and perfusion in healthy older adults.

Authors:  Brittany Intzandt; Dalia Sabra; Catherine Foster; Laurence Desjardins-Crépeau; Richard D Hoge; Christopher J Steele; Louis Bherer; Claudine J Gauthier
Journal:  J Cereb Blood Flow Metab       Date:  2019-07-25       Impact factor: 6.200

Review 2.  Inducible nitric oxide synthase: Regulation, structure, and inhibition.

Authors:  Maris A Cinelli; Ha T Do; Galen P Miley; Richard B Silverman
Journal:  Med Res Rev       Date:  2019-06-13       Impact factor: 12.944

3.  Different Molecular Mechanisms Mediate Direct or Glia-Dependent Prion Protein Fragment 90-231 Neurotoxic Effects in Cerebellar Granule Neurons.

Authors:  Stefano Thellung; Elena Gatta; Francesca Pellistri; Valentina Villa; Alessandro Corsaro; Mario Nizzari; Mauro Robello; Tullio Florio
Journal:  Neurotox Res       Date:  2017-05-25       Impact factor: 3.911

4.  Inducible nitric oxide synthase in long-term intermittent hypoxia: hypersomnolence and brain injury.

Authors:  Guanxia Zhan; Polina Fenik; Domenico Pratico; Sigrid C Veasey
Journal:  Am J Respir Crit Care Med       Date:  2005-03-04       Impact factor: 21.405

5.  Angiotensin Converting Enzyme Inhibitors Ameliorate Brain Inflammation Associated with Microglial Activation: Possible Implications for Alzheimer's Disease.

Authors:  Nofar Torika; Keren Asraf; Ella Roasso; Abraham Danon; Sigal Fleisher-Berkovich
Journal:  J Neuroimmune Pharmacol       Date:  2016-08-25       Impact factor: 4.147

6.  Alzheimer's proteins, oxidative stress, and mitochondrial dysfunction interplay in a neuronal model of Alzheimer's disease.

Authors:  Antonella Bobba; Vito A Petragallo; Ersilia Marra; Anna Atlante
Journal:  Int J Alzheimers Dis       Date:  2010-09-02

7.  Nitric oxide activity and isoenzyme expression in the senescence-accelerated mouse p8 model of Alzheimer's disease: effects of anti-amyloid antibody and antisense treatments.

Authors:  Abbas K Ali; William A Banks; Vijaya B Kumar; Gul N Shah; Jessica L Lynch; Susan A Farr; Melissa A Fleegal-DeMotta; John E Morley
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-06-16       Impact factor: 6.053

8.  Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease.

Authors:  Alon Monsonego; Victor Zota; Arnon Karni; Jeffery I Krieger; Amit Bar-Or; Gal Bitan; Andrew E Budson; Reisa Sperling; Dennis J Selkoe; Howard L Weiner
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

9.  Hippocampal hyperperfusion in Alzheimer's disease.

Authors:  David C Alsop; Melynda Casement; Cedric de Bazelaire; Tamara Fong; Daniel Z Press
Journal:  Neuroimage       Date:  2008-06-17       Impact factor: 6.556

Review 10.  Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.

Authors:  Elisa Zuccarello; Erica Acquarone; Elisa Calcagno; Elentina K Argyrousi; Shi-Xian Deng; Donald W Landry; Ottavio Arancio; Jole Fiorito
Journal:  Biochem Pharmacol       Date:  2020-01-21       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.